NCT03701581View on ClinicalTrials.gov

4-aminopyridine Treatment for Nerve Injury

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 5, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2028

Conditions
Nerve InjuryProstate Cancer
Interventions
DRUG

4-Aminopyridine

FDA-approved tablets.

OTHER

Placebo

Placebo will be tooled to look similar to the study drug.

Trial Locations (2)

14602

TERMINATED

University of Rochester, Rochester

85724

RECRUITING

University of Arizona, Tucson

All Listed Sponsors
lead

John Elfar

OTHER